NCT04704661 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
13 trialsNCT05514132 2026-03-09
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT06929260 2026-01-22
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
AstraZeneca
Phase 1 Terminated
NCT03328273 2026-01-12
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 1 Active not recruiting
NCT04550104 2025-12-19
CONCORDE
University of Leeds
Phase 1 Recruiting
NCT03770429 2025-09-29
AZD6738 for Patients With Progressive MDS or CMML
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT02223923 2025-08-01
Patriot
Royal Marsden NHS Foundation Trust
Phase 1 Unknown
NCT06754761 2025-01-01
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
AstraZeneca
Phase 1 Not yet recruiting
NCT05469919 2024-08-02
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed
NCT02630199 2022-06-15
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Samsung Medical Center
Phase 1 Completed
NCT03022409 2021-08-10
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
AstraZeneca
Phase 1 Completed
NCT03669601 2021-06-04
ATRiUM
Cambridge University Hospitals NHS Foundation Trust
Phase 1 Unknown